4 - Acasti Pharma Inc. (0001444192) (Issuer)

LAVAL, QC, June 22, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced the appointment of W. Taylor Kimberly, MD, PhD, Alejandro A. Rabinstein, MD and Sherry H-Y. Chou, MD to its Scientific Advisory Board. "We are extremely pleased to add eminent physicians with a deep understanding of aSAH and neurocritical care to the Acasti Scientific Advisory Board," commented Prashant Kohli, CEO of Acasti. "As we continue to focus our efforts squarely on the advanc

LAVAL, QC, April 4, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST), a late-stage specialty pharma company advancing drug candidates for rare and orphan diseases, today announced the appointment of Prashant Kohli as Acasti's new Chief Executive Officer, succeeding Jan D'Alvise. The parties have mutually agreed to part ways, and Ms. D'Alvise will be stepping down from the board. Prashant Kohli has served as Chief Commercial Officer of Acasti since 2022. Mr. Kohli has over 20 years of commercialization experience leading strategy, sales, marketing, and product management. Recently, Mr. Kohli was VP, Commercial Operations of Acasti and at Grace Therapeutics, p

LAVAL, Québec, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced today the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") which was held virtually on Wednesday September 28, 2022. Election of Directors All five (5) nominees listed in the proxy statement dated August 31, 2022 (the "Proxy Statement"), being Jean Marie (John) Canan, Jan D'Alvise, Donald Olds, Vimal Kavuru and Michael L. Derby were elected as directors of Acasti at the Meeting to serve for a te

LAVAL, Quebec, March 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST) today announces that it has appointed Michael L. Derby to its Board of Directors. "Michael is a successful pharma industry leader whose extensive involvement in drug repurposing and his passion for developing and commercializing innovative products that positively impact patients' lives will prove to be invaluable as we advance our three lead clinical assets," stated Dr. Roddy Carter, Chairman of the Board of Acasti. "We anticipate benefitting from his perspective and broad experience." Mr. Derby brings more than two decades of experience and a proven track record wit

LAVAL, Québec, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti") (NASDAQ:ACST, TSXV:ACST), announced today the completion of its previously disclosed acquisition of Grace Therapeutics, Inc. ("Grace") via merger. The successful completion of the merger positions Acasti to build a premier, late-stage specialty pharma company focused on rare diseases. Based on management's current forecasts, Acasti expects to have enough cash on its balance sheet following the merger to provide at least two years of operating runway. The combined companies will be led by Jan D'Alvise as President and Chief Executive Officer, under the oversight of Acasti's newly elected Board of Directors, compr

PRINCETON, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) formerly Acasti Pharma Inc. (NASDAQ:ACST) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs, today announced that Chief Executive Officer Prashant Kohli will participate the following investor and industry networking events during the month of January 2025. 14th Annual LifeSci Partners Corporate Access Event – (January 13, 2025) BIO One-on-One Partnering™ – (Ja

PRINCETON, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) formerly Acasti Pharma Inc. (NASDAQ:ACST) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs, today announced that the Company will be participating in the mid-year clinical meeting of the American Society of Health-System Pharmacists (ASHP) to be held December 8–12, 2024, in New Orleans, LA. "As we look forward to data readout from our Phase 3 STRIVE-ON trial

Name Change Reflects Extensive Scientific and Corporate Brand Equity Previously Established under Grace Therapeutics Grace Therapeutics will begin trading on Nasdaq under the trading symbol "GRCE" effective October 28, 2024 Virtual Key Opinion Leader Event to be held on November 20th PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTx-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that it is changing its name to Grace Therapeutics, Inc. (Grace Therapeutics).

PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that patient enrollment has been completed in the Company's Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial–NCT05995405). The STRIVE-ON trial is a prospective, open-label, randomized (1:1 ratio), parallel group trial of GTX-104 compared with oral nimodipine, in 100 patients hospitalized for aSAH. Approximately 25 hospitals in the U.S. are participating. "We are ex

PRINCETON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that Prashant Kohli, Chief Executive Officer of Acasti, will present live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on September 19th 2024. To register for the event and access the Acasti presentation webcast, click on the link below. Life Sciences Investor Forum Date: September 19, 2024 Time: 12:30 PM EDT O

PRINCETON, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference, to be held September 9th – 11th in New York, NY. Prashant Kohli, Chief Executive Officer of Acasti, will be available for one-on-meetings on September 9th and 10th. H.C. Wainwright 26th Annual Global Investment Conference Title: Acasti Corporate Presentation P

Surpassed 50% Enrollment Milestone in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104Company Anticipates Completion of Patient Enrollment in the STRIVE-ON Trial in Late 2024 to Early 2025, with NDA Submission on Track for 1H Calendar 2025Projected Cash Runway into Second Calendar Quarter 2026 PRINCETON, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced financial results and business highlights for the quarter ended June 30,

PRINCETON, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that the Company's pivotal Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial–NCT05995405) has exceeded the 50% enrollment milestone. The STRIVE-ON trial, a prospective, open-label, randomized (1:1 ratio), parallel group trial of GTX-104 compared with oral nimodipine in 100 patients hospitalized for aSAH, initiated patient enrollment in October of 2023. The primary end

Patient Enrollment in Pivotal STRIVE-ON Phase 3 Safety Trial for GTX-104 On-Track for Potential NDA Submission in 1H Calendar 2025Projected Cash Runway into Second Calendar Quarter 2026 PRINCETON, N.J., June 21, 2024 (GLOBE NEWSWIRE) --  Acasti Pharma Inc. (NASDAQ:ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced financial results and business highlights for the year ended March 31, 2024. "During the past year we continued to execute our focused strategy around our biggest value d

PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel, injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that the Company will be participating in the BIO International Convention taking place at the San Diego Convention Center from June 3-6, 2024. During the conference, Prashant Kohli, Chief Executive Officer of Acasti, will host meetings with pharmaceutical executives to explore partnership and strategic opportunities for the Company's asset portfolio. To connect durin

Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced financial and operational results for the third quarter ended December 31, 2022 Recent Highlights The Company anticipates receiving clarifying guidance from the Food and Drug Administration (FDA) on its proposed phase 3 study design for GTX-104 through a written Type C meeting in the first calendar quarter of 2023. The Company expects that favorable FDA guidance would allow Acasti

Call to be held on Tuesday, February 14th at 1:00 PM Eastern Time LAVAL, QB, Feb. 7, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it will host a conference call at 1:00 PM Eastern Time on Tuesday, February 14, 2023, to discuss the Company's corporate progress and other developments, as well as financial results for third quarter 2023 ended December 31, 2022. The conference call will be a

LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it will host a conference call on Tuesday, January 10, 2023 at 4:30 p.m. ET to review the recently reported preliminary topline results from two separate Phase 1 pharmacokinetic (PK) studies for GTX-101 and GTX-102. Both studies successfully met all target outcome measures. The conference call will be available via telephone by dialing toll free 844-836-8745 for U.S. callers or +1 412-317-6797 for international callers. A webca

Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced financial and operational results for the second quarter ended September 30, 2022. Recent Highlights The Company expects to receive guidance from the Food and Drug Administration (FDA) on its proposed phase 3 study design for GTX-104 in the form of a Type C meeting by the end of 2022 or early in the first calendar quarter of 2023. This FDA guidance should allow the Company to init

LAVAL, Quebec, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it will host a conference call at 1:00 PM Eastern Time on Monday, November 14, 2022, to discuss the Company's corporate progress and other developments, as well as financial results for second quarter 2023 ended September 30, 2022. The conference call will be available via telephone by dialing toll free 844-836-8745 for U.S. callers or +1 412-317-6797 for international callers. A webcast of the call may be accessed at https://a

LAVAL, Québec, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced financial and operational results for the first quarter ended June 30, 2022. Recent Highlights The Company is preparing the GTX-104 PK bridging study results for submission to the U.S. Food and Drug Administration (FDA) in calendar Q3. The Company also plans to submit the proposed design for the Phase 3 safety study along with a request for a Type C meeting with the FDA to confirm the Phase 3 plans and obtain the agency's feedback

Call to be held on Thursday, August 11th at 1:00 PM Eastern Time LAVAL, Quebec, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), today announced that it will host a conference call at 1:00 PM Eastern Time on Thursday, August 11, 2022, to discuss the Company's corporate progress and other developments, as well as financial results for first quarter 2023 ended June 30, 2022. The conference call will be available via telephone by dialing toll free 844-836-8745 for U.S. callers or +1 412-317-6797 for international callers. A webcast of the call may be accessed at https://app.webinar.net/972kwK4obMY or on the Company's Investor Relatio

Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, June 21, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced financial and operational results for the fiscal year ended March 31, 2022. Recent Highlights Acasti's 3 lead programs are on schedule to initiate new clinical trials in the second half of calendar 2022 including: GTX-104 – Initiate Phase 3 safety trial (Q4 calendar year) GTX-102 – Initiate PK Bridging Study (Q3 calendar year)GTX-101 – Initiate Single Dose and Multiple Ascending D

LAVAL, Quebec, June 16, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), today announced that it will host a conference call at 1:00 PM Eastern Time on Tuesday, June 21, 2022, to discuss the Company's corporate progress and other developments, as well as financial results for fiscal year 2022 ended March 31, 2022. The conference call will be available via telephone by dialing toll free 844-836-8745 for U.S. callers or +1 412-317-5499 for international callers and using entry code 316432. A webcast of the call may be accessed at https://app.webinar.net/RLkpwLG5mAx or on the Company's Investor Relations section of the website: https://www.aca

Bioavailability of IV GTX-104 compared favorably with the oral formulation of nimodipine, and no serious adverse events observed for GTX-104 Phase 3 remains on track to start before year-end A conference call to discuss the results scheduled for Wednesday May 18th at 1:00 PM Eastern Time LAVAL, Québec, May 18, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST) announced today that the top line results of its pharmacokinetic (PK) bridging study with IV GTX-104, the Company's lead drug candidate for the treatment of Subarachnoid Hemorrhage (SAH), met all its planned study endpoints. The primary objective of the study was to evalu

3/A - Acasti Pharma Inc. (0001444192) (Issuer)

3 - Acasti Pharma Inc. (0001444192) (Issuer)

4/A - Acasti Pharma Inc. (0001444192) (Issuer)

4/A - Acasti Pharma Inc. (0001444192) (Issuer)

4 - Acasti Pharma Inc. (0001444192) (Issuer)

4 - Acasti Pharma Inc. (0001444192) (Issuer)

4 - Acasti Pharma Inc. (0001444192) (Issuer)

4 - Acasti Pharma Inc. (0001444192) (Issuer)

4 - Acasti Pharma Inc. (0001444192) (Issuer)

3 - Acasti Pharma Inc. (0001444192) (Issuer)

SC 13G - Acasti Pharma Inc. (0001444192) (Subject)

SC 13G - Acasti Pharma Inc. (0001444192) (Subject)

SC 13G - Acasti Pharma Inc. (0001444192) (Subject)

Oppenheimer initiated coverage of Acasti Pharma with a rating of Outperform and set a new price target of $6.00

Oppenheimer initiated coverage of Acasti Pharma with a rating of Outperform and set a new price target of $6.00